Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marina Bacac

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
Frontiers in Oncology|February 22, 2021
Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor ActivityJohannes Sam, Sara Colombetti, Tanja Fauti, et al.
Nature Biomedical Engineering|December 19, 2023
Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroidsMarius F Harter, Timothy Recaldin, Regine Gerard, et al.
Cancer Immunology Research|August 9, 2015
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory ReceptorsDaniela S Thommen, Jens Schreiner, Philipp Müller, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cellsMi He, Bhavesh Soni, Petra C Schwalie, et al.
Journal for Immunotherapy of Cancer|January 22, 2022
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacyGabrielle Leclercq, Hélène Haegel, Alberto Toso, et al.
Mabs|March 18, 2016
XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancerJuergen M Schanzer, Katharina Wartha, Ekkehard Moessner, et al.
Theranostics|February 14, 2022
Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagersAlvaro Teijeira, Itziar Migueliz, Saray Garasa, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 18, 2018
The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In VivoAdam Palazzo, Sylvia Herter, Laura Grosmaire, et al.
Blood Advances|December 23, 2021
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphomaAnn-Marie E Bröske, Koorosh Korfi, Anton Belousov, et al.
Oncoimmunology|April 9, 2016
Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptorJens Schreiner, Daniela S Thommen, Petra Herzig, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Frontiers in Oncology|February 22, 2021
Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor ActivityJohannes Sam, Sara Colombetti, Tanja Fauti, et al.
Nature Biomedical Engineering|December 19, 2023
Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroidsMarius F Harter, Timothy Recaldin, Regine Gerard, et al.
Cancer Immunology Research|August 9, 2015
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory ReceptorsDaniela S Thommen, Jens Schreiner, Philipp Müller, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cellsMi He, Bhavesh Soni, Petra C Schwalie, et al.
Journal for Immunotherapy of Cancer|January 22, 2022
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacyGabrielle Leclercq, Hélène Haegel, Alberto Toso, et al.
Mabs|March 18, 2016
XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancerJuergen M Schanzer, Katharina Wartha, Ekkehard Moessner, et al.
Theranostics|February 14, 2022
Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagersAlvaro Teijeira, Itziar Migueliz, Saray Garasa, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 18, 2018
The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In VivoAdam Palazzo, Sylvia Herter, Laura Grosmaire, et al.
Blood Advances|December 23, 2021
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphomaAnn-Marie E Bröske, Koorosh Korfi, Anton Belousov, et al.
Oncoimmunology|April 9, 2016
Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptorJens Schreiner, Daniela S Thommen, Petra Herzig, et al.
Pageof 8